David Abrams - Abrams Capital Management 13F Activity & Position Changes (Q4 2023)

According to the SEC 13F filed on Feb 09, 2024, the Abrams Capital Management portfolio showed several notable changes in holdings as of quarter-end Dec 31, 2023. The activity included new positions, additions to existing holdings, reductions, and complete exits, providing a clear view of how the portfolio evolved during the quarter.

During Q4 2023, the filing reported:

New Buys - None reported

Increases - None reported

Reductions - Meta Platforms, Inc., Teva Pharmaceutical Industries , USCB Financial Holdings, Inc.

Complete Exits - None reported

These updates highlight how the portfolio adjusted across different sectors and market conditions, offering insights into allocation shifts and investment trends.

Date	Symbol	Name	Type	Change Qty	% Change	Value	Remaining
Q4 2023	META Meta Platforms, Inc.	Meta Platforms, Inc.	Sell	-216,924	-23.4%	$251.86M	711,550
Q4 2023	TEVA Teva Pharmaceutical Industries	Teva Pharmaceutical Industries	Sell	-1,969,597	-24.7%	$62.61M	5,996,836
Q4 2023	USCB USCB Financial Holdings, Inc.	USCB Financial Holdings, Inc.	Sell	-499,299	-76.9%	$1.83M	149,786